观点网讯:2月26日,映恩生物港股IPO招股书正式失效。据了解,该公司于2024年8月26日递交的招股书在满6个月后,于2025年2月26日到期失效。作为抗体偶联药物(ADC)领域的全球领跑者,映恩生物专注于为癌症和自身免疫性疾病患者研发新一代创新疗法。公司依托其领先的ADC技术平台,已建立起多条具有差异化优势的管线,并致力于通过这些管线革新癌症治疗模式,为全球患者提供更有效的治疗方案。此次招股书...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.